Preoperative defining system for pancreatic head cancer considering surgical resection

Seok Jeong Yang, Ho Kyoung Hwang, ChangMoo Kang, Woo Jung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIM: To provide appropriate treatment, it is crucial to share the clinical status of pancreas head cancer among multidisciplinary treatment members. METHODS: A retrospective analysis of the medical records of 113 patients who underwent surgery for pancreas head cancer from January 2008 to December 2012 was performed. We developed preoperative defining system of pancreatic head cancer by describing resectability - tumor location - vascular relationship - adjacent organ involvement - preoperative CA19-9 (initial bilirubin level) - vascular anomaly. The oncologic correlations with this reporting system were evaluated. RESULTS: Among 113 patients, there were 75 patients (66.4%) with resectable, 34 patients (30.1%) with borderline resectable, and 4 patients (3.5%) with locally advanced pancreatic cancer. Mean disease-free survival was 24.8 mo (95%CI: 19.6-30.1) with a 5-year diseasefree survival rate of 13.5%. Pretreatment tumor size 2.4 cm [Exp(B) = 3.608, 95%CI: 1.512-8.609, P = 0.044] and radiologic vascular invasion [Exp(B) = 5.553, 95%CI: 2.269-14.589, P = 0.002] were independent predictive factors for neoadjuvant treatment. Borderline resectability [Exp(B) = 0.222, P = 0.008], pancreatic head cancer involving the pancreatic neck [Exp(B) = 9.461, P = 0.001] and arterial invasion [Exp(B) = 6.208, P = 0.010], and adjusted CA19-9 50 [Exp(B) = 1.972 P = 0.019] were identified as prognostic clinical factors to predict tumor recurrence. CONCLUSION: The suggested preoperative defining system can help with designing treatment plans and also predict oncologic outcomes.

Original languageEnglish
Pages (from-to)6076-6082
Number of pages7
JournalWorld Journal of Gastroenterology
Volume22
Issue number26
DOIs
Publication statusPublished - 2016 Jul 14

Fingerprint

Head and Neck Neoplasms
Pancreatic Neoplasms
Blood Vessels
Neoplasms
Neoadjuvant Therapy
Bilirubin
Disease-Free Survival
Medical Records
Therapeutics
Survival Rate
Recurrence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Yang, Seok Jeong ; Hwang, Ho Kyoung ; Kang, ChangMoo ; Lee, Woo Jung. / Preoperative defining system for pancreatic head cancer considering surgical resection. In: World Journal of Gastroenterology. 2016 ; Vol. 22, No. 26. pp. 6076-6082.
@article{1f6126524f244083a26f01408ebc1e89,
title = "Preoperative defining system for pancreatic head cancer considering surgical resection",
abstract = "AIM: To provide appropriate treatment, it is crucial to share the clinical status of pancreas head cancer among multidisciplinary treatment members. METHODS: A retrospective analysis of the medical records of 113 patients who underwent surgery for pancreas head cancer from January 2008 to December 2012 was performed. We developed preoperative defining system of pancreatic head cancer by describing resectability - tumor location - vascular relationship - adjacent organ involvement - preoperative CA19-9 (initial bilirubin level) - vascular anomaly. The oncologic correlations with this reporting system were evaluated. RESULTS: Among 113 patients, there were 75 patients (66.4{\%}) with resectable, 34 patients (30.1{\%}) with borderline resectable, and 4 patients (3.5{\%}) with locally advanced pancreatic cancer. Mean disease-free survival was 24.8 mo (95{\%}CI: 19.6-30.1) with a 5-year diseasefree survival rate of 13.5{\%}. Pretreatment tumor size 2.4 cm [Exp(B) = 3.608, 95{\%}CI: 1.512-8.609, P = 0.044] and radiologic vascular invasion [Exp(B) = 5.553, 95{\%}CI: 2.269-14.589, P = 0.002] were independent predictive factors for neoadjuvant treatment. Borderline resectability [Exp(B) = 0.222, P = 0.008], pancreatic head cancer involving the pancreatic neck [Exp(B) = 9.461, P = 0.001] and arterial invasion [Exp(B) = 6.208, P = 0.010], and adjusted CA19-9 50 [Exp(B) = 1.972 P = 0.019] were identified as prognostic clinical factors to predict tumor recurrence. CONCLUSION: The suggested preoperative defining system can help with designing treatment plans and also predict oncologic outcomes.",
author = "Yang, {Seok Jeong} and Hwang, {Ho Kyoung} and ChangMoo Kang and Lee, {Woo Jung}",
year = "2016",
month = "7",
day = "14",
doi = "10.3748/wjg.v22.i26.6076",
language = "English",
volume = "22",
pages = "6076--6082",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "26",

}

Preoperative defining system for pancreatic head cancer considering surgical resection. / Yang, Seok Jeong; Hwang, Ho Kyoung; Kang, ChangMoo; Lee, Woo Jung.

In: World Journal of Gastroenterology, Vol. 22, No. 26, 14.07.2016, p. 6076-6082.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preoperative defining system for pancreatic head cancer considering surgical resection

AU - Yang, Seok Jeong

AU - Hwang, Ho Kyoung

AU - Kang, ChangMoo

AU - Lee, Woo Jung

PY - 2016/7/14

Y1 - 2016/7/14

N2 - AIM: To provide appropriate treatment, it is crucial to share the clinical status of pancreas head cancer among multidisciplinary treatment members. METHODS: A retrospective analysis of the medical records of 113 patients who underwent surgery for pancreas head cancer from January 2008 to December 2012 was performed. We developed preoperative defining system of pancreatic head cancer by describing resectability - tumor location - vascular relationship - adjacent organ involvement - preoperative CA19-9 (initial bilirubin level) - vascular anomaly. The oncologic correlations with this reporting system were evaluated. RESULTS: Among 113 patients, there were 75 patients (66.4%) with resectable, 34 patients (30.1%) with borderline resectable, and 4 patients (3.5%) with locally advanced pancreatic cancer. Mean disease-free survival was 24.8 mo (95%CI: 19.6-30.1) with a 5-year diseasefree survival rate of 13.5%. Pretreatment tumor size 2.4 cm [Exp(B) = 3.608, 95%CI: 1.512-8.609, P = 0.044] and radiologic vascular invasion [Exp(B) = 5.553, 95%CI: 2.269-14.589, P = 0.002] were independent predictive factors for neoadjuvant treatment. Borderline resectability [Exp(B) = 0.222, P = 0.008], pancreatic head cancer involving the pancreatic neck [Exp(B) = 9.461, P = 0.001] and arterial invasion [Exp(B) = 6.208, P = 0.010], and adjusted CA19-9 50 [Exp(B) = 1.972 P = 0.019] were identified as prognostic clinical factors to predict tumor recurrence. CONCLUSION: The suggested preoperative defining system can help with designing treatment plans and also predict oncologic outcomes.

AB - AIM: To provide appropriate treatment, it is crucial to share the clinical status of pancreas head cancer among multidisciplinary treatment members. METHODS: A retrospective analysis of the medical records of 113 patients who underwent surgery for pancreas head cancer from January 2008 to December 2012 was performed. We developed preoperative defining system of pancreatic head cancer by describing resectability - tumor location - vascular relationship - adjacent organ involvement - preoperative CA19-9 (initial bilirubin level) - vascular anomaly. The oncologic correlations with this reporting system were evaluated. RESULTS: Among 113 patients, there were 75 patients (66.4%) with resectable, 34 patients (30.1%) with borderline resectable, and 4 patients (3.5%) with locally advanced pancreatic cancer. Mean disease-free survival was 24.8 mo (95%CI: 19.6-30.1) with a 5-year diseasefree survival rate of 13.5%. Pretreatment tumor size 2.4 cm [Exp(B) = 3.608, 95%CI: 1.512-8.609, P = 0.044] and radiologic vascular invasion [Exp(B) = 5.553, 95%CI: 2.269-14.589, P = 0.002] were independent predictive factors for neoadjuvant treatment. Borderline resectability [Exp(B) = 0.222, P = 0.008], pancreatic head cancer involving the pancreatic neck [Exp(B) = 9.461, P = 0.001] and arterial invasion [Exp(B) = 6.208, P = 0.010], and adjusted CA19-9 50 [Exp(B) = 1.972 P = 0.019] were identified as prognostic clinical factors to predict tumor recurrence. CONCLUSION: The suggested preoperative defining system can help with designing treatment plans and also predict oncologic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84978194675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978194675&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i26.6076

DO - 10.3748/wjg.v22.i26.6076

M3 - Article

C2 - 27468199

AN - SCOPUS:84978194675

VL - 22

SP - 6076

EP - 6082

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 26

ER -